Fig. 3

Synergistic effects of Gilteritinib and ATO in FLT3-ITD cell lines. a–d MV4-11 and MOLM13 cells were treated with Gilteritinib (2.5 nM) and/or ATO (0.5 µM) for 48 h and cell apoptosis was determined by flow cytometry. DMSO treated cells served as a control. Data are shown as the mean ± SD. **P < 0.01, ***P < 0.001. e, f Cellular morphology of the MV4-11 and MOLM13 cells treated with Gilteritinib (2.5 nM) and/or ATO (0.5 µM) for 48 h (Wright–Geimsa staining; magnification, ×1000). Typical features of apoptotic cells were marked by arrows. g, h Transwell assay of MV4-11 and MOLM13 cells treated with Gilteritinib (2.5 nM) and/or ATO (0.5 µM) for 48 h was performed. i, j Cell cycle analysis of MV4-11 cells treated with Gilteritinib (2.5 nM) and/or ATO (0.5 µM) for 48 h was determined by flow cytometry. Data are shown as the mean ± SD. *P < 0.05